Activity
Vertex Pharmaceuticals is dedicated to the research, development, and production of innovative medicines for people with serious and difficult-to-treat diseases, with a focus on specialized markets.
History
Vertex has been developing transformative medicines for over 20 years, particularly in the area of cystic fibrosis. The company has evolved from a small research startup to a global company with research and development facilities and commercial offices around the world, including its headquarters in Boston and London. Its history is characterized by continuous investment in scientific innovation and the expansion of its portfolio of therapies for various serious diseases.
Product types
Vertex offers U.S.-approved medicines such as ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), CASGEVY (exagamglogene autotemcel), JOURNAVX (suzetrigine), KALYDECO (ivacaftor), ORKAMBI (lumacaftor/ivacaftor), SYMDEKO (tezacaftor/ivacaftor and ivacaftor), and TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor). Its core areas include treatments for cystic fibrosis, blood disorders such as beta-thalassemia and sickle cell disease, acute pain, kidney disease, and type 1 diabetes. It also develops cell and gene therapies and offers patient support programs.
Mission
Vertex's fundamental purpose is to invest in scientific innovation to create transformative medicines for people with serious diseases, with the goal of improving their lives. Its long-term goal is to expand global access to its therapies and continue developing solutions for diseases with high unmet medical need.
